|Articles|September 25, 2016 (Updated: November 15, 2020)
Tufts CSDD Releases Findings from Diabetes Study
September 26, 2016
Advertisement
According to results of a new study by the Tufts Center for the Study of Drug Development, the development process for new diabetes and non-diabetes endocrine drugs is riskier compared to all drug development. The study examined the development pathways and characteristics of 27 diabetes and 34 non-diabetes endocrine drugs.
Read the full release
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Patent Term Extension: Challenges with Defining and Claiming Approved Biologics
2
Novo Nordisk Invests $506 Million in Ireland Manufacturing Facility Expansion
3
FDA Approves New Indication of Palynziq for Patients 12 Years and Older with Phenylketonuria
4
Real-World Data Brings New Insights to Natural History of Disease Studies
5